Literature DB >> 22842662

Prediction of radiation pneumonitis in lung cancer patients: a systematic review.

Xiao-Jing Zhang1, Jian-Guo Sun, Jie Sun, Hua Ming, Xin-Xin Wang, Lei Wu, Zheng-Tang Chen.   

Abstract

PURPOSE: Factors prediction in the development of radiation pneumonitis (RP) remains unclear. A meta-analysis about this was performed. MATERIALS: Articles were searched in February 2012 from PubMed, EMBASE, Cochrane Library and CNKI (Chinese Journal Full-text Database) using the keywords "lung cancer," "radiation pneumonitis" or "radiation lung injury." The outcome was the RP incidence. We pooled the data using RevMan 5.1 software and tested the statistical heterogeneity.
RESULTS: We included the following factors: age, gender, weight loss, smoking history, complications, performance status, pre-radiation therapy (RT) pulmonary function, TNM, histological type, tumor location, pre-RT surgery, RT combined with chemotherapy (RCT), RT/RCT combined with amifostine, plasma end/pre-RT TGF-β1 ratio and irradiation volume. The significant risk factors for RP ≥ grade 2 were patients with chronic lung disease, tumor located in the middle or lower lobe, without pre-RT surgery, RCT, plasma end/pre-RT TGF-β1 ratio ≥1 and gross tumor volume (GTV). Following factors were identified significant for RP, including tumor located not in the upper lobe, smokers, combined with chronic lung diseases or diabetes mellitus, low pre-RT pulmonary function, RCT, RT/RCT without amifostine and plasma end/pre-RT TGF-β1 ratio ≥1. Dose-volume parameters included the average of mean lung dose (MLD) of disease lung, GTV and V (5), V (10) (≥34 %), V (20) (≥25 %), V (30) (≥18 %) of bilateral lung.
CONCLUSIONS: More attention should be paid to the levels of patients' pulmonary function, plasma TGF-β1 and dose-volume histogram (DVH). Rigorous studies are needed to identify the relationship between the above-mentioned factors and RP ≥grade 1 or 3.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22842662     DOI: 10.1007/s00432-012-1284-1

Source DB:  PubMed          Journal:  J Cancer Res Clin Oncol        ISSN: 0171-5216            Impact factor:   4.553


  74 in total

1.  ATM polymorphisms are associated with risk of radiation-induced pneumonitis.

Authors:  Li Zhang; Ming Yang; Nan Bi; Mingjing Fang; Tong Sun; Wei Ji; Wen Tan; Lujun Zhao; Dianke Yu; Dongxin Lin; Luhua Wang
Journal:  Int J Radiat Oncol Biol Phys       Date:  2010-02-18       Impact factor: 7.038

2.  The impact of heterogeneity correction on dosimetric parameters that predict for radiation pneumonitis.

Authors:  Daniel T Chang; Kenneth R Olivier; Christopher G Morris; Chihray Liu; James F Dempsey; Rashmi K Benda; Jatinder R Palta
Journal:  Int J Radiat Oncol Biol Phys       Date:  2006-01-19       Impact factor: 7.038

3.  Correlation of dosimetric factors and radiation pneumonitis for non-small-cell lung cancer patients in a recently completed dose escalation study.

Authors:  Ellen D Yorke; Andrew Jackson; Kenneth E Rosenzweig; Louise Braban; Steven A Leibel; C Clifton Ling
Journal:  Int J Radiat Oncol Biol Phys       Date:  2005-06-04       Impact factor: 7.038

4.  Radiation pneumonitis following twice-daily radiotherapy with concurrent carboplatin and paclitaxel in patients with stage III non-small-cell lung cancer.

Authors:  Hiroki Kobayashi; Takashi Uno; Koichi Isobe; Naoyuki Ueno; Miho Watanabe; Rintaro Harada; Yuichi Takiguchi; Koichiro Tatsumi; Hisao Ito
Journal:  Jpn J Clin Oncol       Date:  2010-01-18       Impact factor: 3.019

5.  Risk factors for development of radiation pneumonitis following radiation therapy with or without chemotherapy for lung cancer.

Authors:  Y Segawa; N Takigawa; M Kataoka; I Takata; N Fujimoto; H Ueoka
Journal:  Int J Radiat Oncol Biol Phys       Date:  1997-08-01       Impact factor: 7.038

6.  Predicting the risk of symptomatic radiation-induced lung injury using both the physical and biologic parameters V(30) and transforming growth factor beta.

Authors:  X L Fu; H Huang; G Bentel; R Clough; R L Jirtle; F M Kong; L B Marks; M S Anscher
Journal:  Int J Radiat Oncol Biol Phys       Date:  2001-07-15       Impact factor: 7.038

7.  Risk factors of pneumonitis following chemoradiotherapy for lung cancer.

Authors:  M Yamada; S Kudoh; K Hirata; T Nakajima; J Yoshikawa
Journal:  Eur J Cancer       Date:  1998-01       Impact factor: 9.162

8.  Transforming growth factor-beta plasma dynamics and post-irradiation lung injury in lung cancer patients.

Authors:  Alena Novakova-Jiresova; Mieke M Van Gameren; Rob P Coppes; Harm H Kampinga; Harry J M Groen
Journal:  Radiother Oncol       Date:  2004-05       Impact factor: 6.280

9.  Phase II study of three-dimensional conformal radiotherapy and concurrent mitomycin-C, vinblastine, and cisplatin chemotherapy for Stage III locally advanced, unresectable, non-small-cell lung cancer.

Authors:  Sang-wook Lee; Eun Kyung Choi; Jung Shin Lee; Sang Do Lee; Cheolwon Suh; Sang-We Kim; Woo Sung Kim; Seung Do Ahn; Byong Yong Yi; Jong Hoon Kim; Young Ju Noh; Su Ssan Kim; Younsuck Koh; Dong Soon Kim; Won-Dong Kim
Journal:  Int J Radiat Oncol Biol Phys       Date:  2003-07-15       Impact factor: 7.038

10.  [Clinical study of radiation pneumonitis over 10 years].

Authors:  H Watanabe; A Suga; Y Tsuchihashi; A Hori; K Kawakami; H Masaki; M Akiyama; K Ohishi; A Takahashi; T Nagatake
Journal:  Nihon Kyobu Shikkan Gakkai Zasshi       Date:  1995-04
View more
  70 in total

1.  Blockade of Aquaporin 4 Inhibits Irradiation-Induced Pulmonary Inflammation and Modulates Macrophage Polarization in Mice.

Authors:  Yuhui Li; Hongda Lu; Xiaojuan Lv; Qiu Tang; Wangxia Li; Hongfei Zhu; Yuan Long
Journal:  Inflammation       Date:  2018-12       Impact factor: 4.092

2.  Radiation-induced lung toxicity in non-small-cell lung cancer: Understanding the interactions of clinical factors and cytokines with the dose-toxicity relationship.

Authors:  Peter G Hawkins; Philip S Boonstra; Stephen T Hobson; Jason W D Hearn; James A Hayman; Randall K Ten Haken; Martha M Matuszak; Paul Stanton; Gregory P Kalemkerian; Nithya Ramnath; Theodore S Lawrence; Matthew J Schipper; Feng-Ming Spring Kong; Shruti Jolly
Journal:  Radiother Oncol       Date:  2017-09-23       Impact factor: 6.280

Review 3.  HSPB1 polymorphisms might be associated with radiation-induced damage risk in lung cancer patients treated with radiotherapy.

Authors:  Xiaofeng Li; Sheng Xu; Yu Cheng; Jun Shu
Journal:  Tumour Biol       Date:  2016-02-13

4.  Impact of single-nucleotide polymorphisms on radiation pneumonitis in cancer patients.

Authors:  Cheng-Xian Guo; Jing Wang; Li-Hua Huang; Jin-Gao Li; Xiang Chen
Journal:  Mol Clin Oncol       Date:  2015-10-30

5.  Clinical features, outcomes and treatment-related pneumonitis in elderly patients with esophageal carcinoma.

Authors:  Jian He; Zhao-Chong Zeng; Shi-Ming Shi; Ping Yang
Journal:  World J Gastroenterol       Date:  2014-09-28       Impact factor: 5.742

6.  Plasma Levels of IL-8 and TGF-β1 Predict Radiation-Induced Lung Toxicity in Non-Small Cell Lung Cancer: A Validation Study.

Authors:  Shulian Wang; Jeff Campbell; Matthew H Stenmark; Jing Zhao; Paul Stanton; Martha M Matuszak; Randall K Ten Haken; Feng-Ming Spring Kong
Journal:  Int J Radiat Oncol Biol Phys       Date:  2017-03-14       Impact factor: 7.038

7.  Inhibition of TBK1 attenuates radiation-induced epithelial-mesenchymal transition of A549 human lung cancer cells via activation of GSK-3β and repression of ZEB1.

Authors:  Wen Liu; Yi-Juan Huang; Cong Liu; Yan-Yong Yang; Hu Liu; Jian-Guo Cui; Ying Cheng; Fu Gao; Jian-Ming Cai; Bai-Long Li
Journal:  Lab Invest       Date:  2014-01-27       Impact factor: 5.662

8.  Validation and optimization of a predictive model for radiation pneumonitis in patients with lung cancer.

Authors:  Charlott Mörth; Ioannis Kafantaris; Markus Castegren; Antonios Valachis
Journal:  Oncol Lett       Date:  2016-06-06       Impact factor: 2.967

9.  Advances in targeting the transforming growth factor β1 signaling pathway in lung cancer radiotherapy.

Authors:  Zhonghua Lu; Yiting Tang; Judong Luo; Shuyu Zhang; Xifa Zhou; Lei Fu
Journal:  Oncol Lett       Date:  2017-09-18       Impact factor: 2.967

10.  Do angiotensin-converting enzyme inhibitors reduce the risk of symptomatic radiation pneumonitis in patients with non-small cell lung cancer after definitive radiation therapy? Analysis of a single-institution database.

Authors:  Hongmei Wang; Zhongxing Liao; Yan Zhuang; Ting Xu; Quynh-Nhu Nguyen; Lawrence B Levy; Michael O'Reilly; Kathryn A Gold; Daniel R Gomez
Journal:  Int J Radiat Oncol Biol Phys       Date:  2013-10-22       Impact factor: 7.038

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.